Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
NEJM • 2/25/2026 – 2/26/2026
Summary
A Phase 1 study of Rezatapopt, a p53 reactivator, was conducted in tumors with the TP53 Y220C mutation. The findings were published in the New England Journal of Medicine, Volume 394, Issue 9, on pages 872-883, dated February 26, 2026.
Advertisement
Lindy Score Breakdown (V4.2)
49d
Age
1
Sources
from cluster
1165
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1165/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1165/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 49 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Flawed study on the antidepressant Paxil came with a cautionary note — if you knew how to find it
Stat News • Today
STAT+: AI could check millions of CT scans for heart risk. Who will pay for it?
Stat News • Today
STAT+: Pharmalittle: We’re reading about FDA seeking more data on a Lilly obesity pill, a pharma 340B win, and more
Stat News • Today
STAT+: A $15 AI test, Project Glasswing, and how Doctronic pilot blindsided Utah medical board
Stat News • Today
STAT+: New Bain biotech startup, building on BMS drugs, gets a name and a CEO
Stat News • Today
Opinion: Medical schools must continue to teach students about structural barriers to care
Stat News • Today
STAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill
Stat News • 2 days ago
On positioning nurses as health experts
Stat News • 2 days ago
STAT+: Federal judge tosses California No Surprises Act lawsuit against HaloMD
Stat News • 1 day ago
STAT+: Trump goes soft on insurance, and a medical underwriting chart
Stat News • 2 days ago
